Search research articles
Contact Us
Filters
Showing results (541-550 of 1,058) with videos related to
Page
of 106
Sort By:
Blood
|
May 13, 2004
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
John C Byrd, Kanti Rai, Bercedis L Peterson, et al.
Nucleic Acids Research
|
August 20, 2013
Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis
Rajbir Singh, Amir Mortazavi, Kelly H Telu, et al.
Journal of Translational Medicine
|
February 11, 2020
CLEAR: coverage-based limiting-cell experiment analysis for RNA-seq
Logan A Walker, Michael G Sovic, Chi-Ling Chiang, et al.
Blood Advances
|
July 14, 2022
Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
Jonathan M Hyak, Ying Huang, Kerry A Rogers, et al.
Leukemia
|
December 10, 2014
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib
D Guinn, A S Ruppert, K Maddocks, et al.
Plos One
|
February 6, 2013
Germline allele-specific expression of DAPK1 in chronic lymphocytic leukemia
Quan-Xiang Wei, Rainer Claus, Thomas Hielscher, et al.
Leukemia & Lymphoma
|
October 29, 2009
Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia
Thomas S Lin, Louie Naumovski, Philip S Lecane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2005
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy
John C Byrd, John G Gribben, Bercedis L Peterson, et al.
British Journal of Haematology
|
February 3, 2009
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia
Rosa Lapalombella, Aruna Gowda, Trupti Joshi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2010
FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma
Qing Liu, Lapo Alinari, Ching-Shih Chen, et al.
Page
of 106
Search research articles
Search
Showing results (541-550 of 1,058) with videos related to
Sort By:
Page
of 106
Blood
|
May 13, 2004
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
John C Byrd, Kanti Rai, Bercedis L Peterson, et al.
Nucleic Acids Research
|
August 20, 2013
Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis
Rajbir Singh, Amir Mortazavi, Kelly H Telu, et al.
Journal of Translational Medicine
|
February 11, 2020
CLEAR: coverage-based limiting-cell experiment analysis for RNA-seq
Logan A Walker, Michael G Sovic, Chi-Ling Chiang, et al.
Blood Advances
|
July 14, 2022
Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
Jonathan M Hyak, Ying Huang, Kerry A Rogers, et al.
Leukemia
|
December 10, 2014
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib
D Guinn, A S Ruppert, K Maddocks, et al.
Plos One
|
February 6, 2013
Germline allele-specific expression of DAPK1 in chronic lymphocytic leukemia
Quan-Xiang Wei, Rainer Claus, Thomas Hielscher, et al.
Leukemia & Lymphoma
|
October 29, 2009
Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia
Thomas S Lin, Louie Naumovski, Philip S Lecane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2005
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy
John C Byrd, John G Gribben, Bercedis L Peterson, et al.
British Journal of Haematology
|
February 3, 2009
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia
Rosa Lapalombella, Aruna Gowda, Trupti Joshi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2010
FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma
Qing Liu, Lapo Alinari, Ching-Shih Chen, et al.
Page
of 106